JPMorgan Reduces Stake in WUXI APPTEC (02359) by Approximately 2.52 Million Shares at HK$119.32 Per Share

WuXi AppTec Receives MSCI AAA ESG Rating and CDP 'A' Scores for Climate and Water

Citi Maintains "Buy" Rating on WUXI APPTEC (02359) with Target Price of HK$142

Global 16% Market Share and 80 Commercial Projects: Wuxi Apptec (02359) Adheres to Doing the Right Thing, with 167 Phase III and Commercialized Small Molecule Pipeline Projects

Embracing Challenges for the Right Cause: WUXI APPTEC (02359) Supports 24 GLP-1 Drugs to Meet Urgent Clinical Needs

WuXi AppTec Highlights Global CRDMO Growth and Innovation Platform in Latest Presentation

Up to 447%! These Pharma Companies Double Profits: WuXi AppTec, Konruns Pharma...

Citi Places WUXI APPTEC (02359) on 90-Day Positive Catalyst Watch with HK$142 Target

CLSA: WUXI APPTEC (02359) Top Pick in China's Pharma CRO/CDMO Sector, Expected to Outperform Peers This Year

JPMorgan: WUXI APPTEC's (02359) Profit Alert Exceeds Expectations, Expects Positive Market Reaction

Highlights from Major Securities Newspapers - January 14, 2026

Hong Kong Stocks Movement | CRO Concept Stocks Lead Gains with WUXI APPTEC (02359) Forecasting Doubled Net Profit; Sector Poised for "Davis Double Play"

Hong Kong Stock Announcement Highlights | WuXi AppTec Forecasts 2025 Net Profit Attributable to Shareholders of Approximately RMB 19.151 Billion, Up ~102.65% YoY

Unstoppable Performance: WuXi AppTec (603259.SH/02359) Surpasses Guidance Again, 2025 Revenue Hits Record 45.456 Billion Yuan

Press Release: WuXi AppTec Issues Positive Profit Alert for the Full Year of 2025

WUXI APPTEC (02359) Issues Profit Alert, Expects Net Profit Attributable to Shareholders of Approximately RMB 19.151 Billion, Up ~102.65% YoY

BRIEF-WuXi AppTec Sees 2025 Net Profit Up 102.7% Y/Y

WuXi AppTec Sees 2025 Net Profit up 102.7& Y/Y

WuXi AppTec (02359) Awards 126,200 Incentive Shares

WuXi AppTec Grants Awards Under 2024 H Share Award and Trust Scheme